# Bloating / Motility / SUDD-SIBO originals (2026-05-10)
Preservation archive created before consolidating the symptom/motility cluster.


---

## Original: topics/sibo-mmc.md

```markdown
---
topic: "SIBO, MMC, and Post-Prandial Bloating in Diverticular Disease"
tags:
  - sibo
  - mmc
  - diverticular-disease
  - bloating
  - bile-acid-diarrhea
  - diet-soda
  - artificial-sweeteners
  - carbonation
  - breath-test
  - prokinetics
  - sudd
  - ibs
  - diagnostics
  - treatment
priority: high
confidence: 0.85
abstract: >-
  Post-prandial bloating most strongly points toward symptom physiology: SIBO/MMC,
  SUDD/IBS overlap, diet load, alcohol effects, or less likely bile-acid diarrhea when watery
  urgency dominates. It remains a symptom differential, not a bleeding explanation; structured
  trials and selective testing matter more than assuming one cause.
related_topics:
  - diverticular-disease
  - bloating-vs-bleeding-risk
  - abdominal-spot-pain-map
  - occult-stool-blood-workup
  - clostridium-butyricum
created: 2026-04-10
last_updated: 2026-05-05
open_questions:
  - "Does the meal-spacing / no-snacking experiment materially reduce post-prandial bloating?"
  - "Does Coke Zero / diet-soda exposure reproducibly trigger same-day bloating, stomach ache, reflux/burning, or stool looseness, or was the current worsening a one-off confounded signal?"
  - "Does stool logging show chronic watery/urgent diarrhea often enough to justify a bile-acid diarrhea question, or should this branch be dropped?"
  - "If symptoms remain disruptive, can a Phnom Penh GI clinician arrange hydrogen + methane breath testing, bile-acid testing, or only clinician-guided empirical management?"
---

# SIBO, MMC Dysfunction, and Post-Prandial Bloating in Diverticular Disease

## Summary

SIBO/MMC dysfunction is a **symptom differential**, not a confirmed diagnosis and not an explanation for stool blood. The current pattern — prominent post-prandial bloating, diverticular disease/SUDD overlap, normalized calprotectin, and ongoing iron/stool-blood monitoring — fits a symptom/motility branch that should run **separately** from the occult-bleeding branch.

Bile-acid diarrhea is a lower-priority branch unless logging shows chronic watery/urgent stool. It can overlap with IBS-D/SUDD symptoms, but bloating alone is not enough to chase bile-acid testing or sequestrants.

The practical question is whether meal spacing, diet-pattern control, clinician review, or accessible testing would change management.

High-priority here means KB tracking and symptom-planning priority, not emergency care unless the red flags listed in [Whole-Profile Seriousness Triage](#sec-whole-profile-triage) appear.

## Why SIBO/MMC Remains Plausible

| Signal | Interpretation |
|---|---|
| Bloating worse after meals | Compatible with carbohydrate fermentation, impaired clearance, visceral hypersensitivity, SUDD/IBS overlap, or alcohol/diet load. |
| Coke Zero / diet soda trigger | Plausible symptom trigger via carbonation volume, caffeine/acid, and non-caloric sweeteners in a sensitive gut; not evidence of bleeding, diverticulitis, or structural injury by itself. |
| Diverticular disease / SUDD | Bacterial overgrowth, microbiota shifts, visceral hypersensitivity, and a 2025 exploratory fecal-bile-acid SUDD signal are reported, but these signals are heterogeneous and do not prove causality in an individual; treat as a symptom branch, not a single-label diagnosis. |
| Calprotectin now normal | Weakens active inflammatory colitis/diverticulitis as the main explanation for current bloating. |
| Positive stool blood / iron drift | Keep on a separate GI-blood-loss pathway; SIBO should not be used to explain it away. |
| Age >50, stress, meal pattern | Plausible MMC/motility contributors; useful for low-risk behavioral experiments. |

## Mechanism and Implications

| Concept | Evidence / context | Implication |
|---|---|---|
| SIBO definition | Excess small-intestinal microbes; aspirate culture threshold often cited as ≥10³ CFU/mL, but clinical work usually uses breath testing. | Diagnosis is imperfect; symptoms alone are not enough. |
| Gas patterns | Hydrogen often maps to diarrhea/urgency; methane is now better called intestinal methanogen overgrowth (IMO) and maps more to constipation/slow transit; hydrogen sulfide remains less standardized. | If testing is done, hydrogen + methane reporting is the minimum useful version. |
| MMC | Fasting “housekeeper” waves clear residual food/bacteria; caloric intake interrupts the cycle. | 4–5 hour meal gaps and no caloric snacks are a low-risk self-test. |
| Diverticular/SUDD overlap | Shared dysmotility, microbiome shifts, visceral hypersensitivity, and possibly bile-acid changes can make SUDD, IBS, BAD, and SIBO clinically hard to separate. | Treat the symptom branch pragmatically; do not over-interpret one label. |
| Bile-acid diarrhea (BAD) | Guidelines treat BAD as a chronic-diarrhea/IBS-D differential, especially with watery stool, urgency, high stool frequency, toilet-proximity burden, ileal disease/resection, cholecystectomy, or radiotherapy. | In this profile, pursue only if the diary shows persistent watery/urgent stool; bloating alone is too weak. |
| Relapse | Recurrence after treatment is common when the motility/root cause remains. | If antibiotics are ever used, relapse prevention matters more than repeating courses indefinitely. |

## Selective Testing

| Test | Strength | Weakness | Role in this case |
|---|---|---|---|
| Glucose hydrogen/methane breath test | Better specificity; cleaner when false positives are a concern. | Can miss distal/ileal SIBO because glucose is absorbed proximally. | Reasonable first formal test if accessible and methane is reported. |
| Lactulose hydrogen/methane breath test | Can sample more distal fermentation. | More transit-confounded; 2024 critical appraisals are especially skeptical in IBS/DGBI-style bloating. | Useful only if interpreted carefully by a clinician. |
| Trio-gas testing | Adds hydrogen sulfide. | Less available; H2S interpretation still emerging. | Nice-to-have, not required locally. |
| Jejunal aspirate | Traditional reference standard. | Invasive, contamination-prone, rarely practical. | Not a default step. |
| Empirical rifaximin response | May support a symptom hypothesis. | Not diagnostic; response can reflect IBS/SUDD/placebo/microbiome effects. | Clinician-guided fallback if testing is unavailable and symptoms justify treatment. |
| BAD tests: SeHCAT, fasting serum C4, 48-hour fecal bile acids; FGF19 mainly adjunct/research | More specific than guessing; BSG/CAG guidelines prefer objective testing where available. | SeHCAT often unavailable; C4/fecal bile acids may be send-out only; FGF19 is less established. | Only ask for this if repeated logs show chronic watery/urgent diarrhea or IBS-D pattern; not for isolated bloating. |

Consensus cutoffs to remember: hydrogen rise ≥20 ppm by 90 minutes; methane ≥10 ppm at any point. Elevated fasting baseline can also be suggestive. Breath testing should be scheduled and interpreted around protocol restrictions for antibiotics, probiotics, prokinetics, prep diet, and fasting; otherwise the result is easy to misread.

## Local Access

Status: **no confirmed public Phnom Penh hydrogen/methane SIBO breath-test provider and no confirmed public bile-acid diarrhea test route**.

| Route | Status | Action |
|---|---|---|
| Biomed Phnom Penh tariff | No public breath / hydrogen / methane / SIBO listing found. 2026-05-04 tariff scrape found cholesterol rows but no SeHCAT, serum C4, FGF19, or fecal bile-acid test. | Do not assume local lab access. |
| Phnom Penh GI / hospital route | GI specialists exist, but public pages did not confirm hydrogen/methane SIBO testing or BAD testing. | Ask directly: “Do you offer hydrogen and methane breath testing for SIBO/IMO? If chronic watery urgency is the main symptom, can you test for bile-acid diarrhea with SeHCAT, serum C4, or fecal bile acids?” |
| Bangkok fallback | Public breath-test options exist; a clear SeHCAT/BAD route still needs direct hospital confirmation. | Fallback only if a formal result would change treatment; not Phnom Penh-first default. |
| Medication access | Rifaximin/neomycin/prucalopride and bile-acid sequestrants such as cholestyramine/colesevelam remain uncertain locally. | Confirm through clinician/hospital pharmacy before building a plan around any drug. |

## Treatment and Relapse Prevention

| Option | Typical role | Caveats |
|---|---|---|
| Meal spacing / no caloric snacks | Lowest-risk MMC support; also a clean meal-spacing experiment. | Not proof of SIBO if it helps. Track meal timing, bloating timing, maximum-width abdomen circumference, stool pattern, pain, visible blood, and weight. |
| Avoid diet soda / carbonated sweet drinks during signal-finding | Low-risk removal trial when Coke Zero or soda water correlates with same-day bloating or ache. | If later re-challenged, test one variable at a time: volume, carbonation, caffeine/cola acid, and non-caloric sweetener are otherwise mixed together. |
| Low-fermentable / modified low-FODMAP trial | Symptom control while the differential is unclear. | Does not prove bleeding-risk reduction and should not become unnecessarily restrictive. |
| Rifaximin | Usual clinician discussion for hydrogen-predominant SIBO; common 14-day protocols use 550 mg TID. | Availability/cost uncertain locally; symptom response is not diagnostic by itself. |
| Rifaximin + neomycin | Methane/IMO discussion when methane is elevated. | Neomycin has ototoxicity/nephrotoxicity concerns; avoid unsupervised use. |
| Bile-acid sequestrant trial | Clinician-led option when BAD is objectively supported or classic chronic watery urgency persists and testing is unavailable. | Can worsen bloating/constipation, bind other medicines/supplements, and is not a clean diagnostic test. Do not self-start for bloating alone. |
| Herbal antimicrobials | Some limited comparative evidence exists. | Product quality/dosing variability is high; not a clean substitute for diagnosis or clinician-guided treatment. |
| Prokinetics | Consider after treatment or when dysmotility/MMC failure is a strong suspected driver. | Off-label for SIBO relapse prevention; prucalopride/low-dose erythromycin require clinician review and interaction/QT risk awareness. |
| Repeat antibiotics | Sometimes needed for relapse. | Should follow recurrent symptoms plus testing/clinical review, not indefinite cycling. |

## SIBO vs BAD vs SUDD vs Diverticulitis

| Feature | SIBO / MMC | Bile-acid diarrhea | SUDD / IBS overlap | Active diverticulitis |
|---|---|---|---|---|
| Main pattern | Post-prandial bloating, distension, gas, altered transit. | Chronic watery/loose stool, urgency, high frequency, toilet-proximity burden; often IBS-D-like. | Recurrent abdominal symptoms with diverticula but no acute inflammation. | Focal pain, fever, systemic inflammatory signs, CT changes. |
| Calprotectin | Can be normal or mildly elevated; normal does not rule out symptoms. | Not the main test; BAD can coexist with normal inflammatory markers. | Often normal/mild. | More likely elevated if colonic inflammation is active. |
| Blood/iron signal | Not enough to explain positive FOB/RBC by itself. | Not enough to explain positive FOB/RBC by itself. | Not enough to dismiss occult blood. | Bleeding/inflammation branches require separate evaluation. |
| CT role | Not a routine bloating test. | Not routine. | Not routine unless structural red flags. | Appropriate when acute diverticulitis/complication signs appear. |
| Treatment implication | Meal spacing, diet-pattern trial, breath-test/clinician logic. | Test first if possible; sequestrant only clinician-led and symptom-targeted. | Symptom management, fiber/diet tolerance, SUDD options. | Clinician-directed acute pathway. |

## Practical Next Steps

1. **Keep the current experiment clean.** Track meal timing, no-snacking windows, bloating onset/peak, morning baseline versus post-meal peak maximum-width abdomen circumference, stool pattern, pain location, visible blood, alcohol/smoking lapses, diet-soda/carbonated-drink exposures, and weight trend. While the Coke Zero signal is live, avoid Coke Zero/diet colas rather than using them as coffee/alcohol substitutes.
2. **Do not chase breath testing, bile-acid testing, or broad microbiome sequencing as standalone priorities.** Use hydrogen/methane breath testing only if accessible and if the result would change treatment. Ask about BAD testing only if logs show repeated watery/urgent diarrhea rather than mainly bloating/distension. Skip broad commercial stool microbiome tests because current consensus does not support them as general dysbiosis/supplement selectors. If iron/B12/diarrhea/weight-loss signals point beyond pure fermentation, use the separate [Celiac + Autoimmune Gastritis + Malabsorption Screen](#sec-malabsorption-screen).
3. **Ask one focused GI question if symptoms persist:** can they arrange hydrogen + methane testing, bile-acid testing when watery urgency dominates, or would they manage empirically after red flags are excluded?
4. **Do not use CT for routine bloating.** Reserve CT abdomen/pelvis for acute diverticulitis signs, severe/persistent focal pain, fever, obstruction, abscess concern, unexplained weight loss, or clinician-directed structural concern.
5. **Keep the bleeding branch separate.** Positive FOB/RBC, ferritin/TSAT/Hb drift, visible bleeding, or alarm symptoms belong in the occult-blood/iron-loss workup, not the SIBO symptom pathway.
6. **If SIBO/IMO or BAD is confirmed or treated clinically:** match therapy to the mechanism, use clinician supervision for antibiotics/prokinetics/sequestrants, and keep meal spacing as the low-risk relapse-prevention anchor.

## Research Trace

- Research mode: clinical decision synthesis + local logistics. Existing KB, cloud-doc symptom pattern, Biomed tariff status, public Phnom Penh/Bangkok logistics, breath-test consensus, BAD/chronic-diarrhea guidelines, Asian-Pacific consensus, SUDD/SIBO literature, 2025 microbiome-testing consensus, and a focused Coke Zero/diet-soda trigger check were integrated through 2026-05-05.
- Evidence anchors: breath-test consensus (PMID: 28321120; PMID: 36214973); BAD guidance/reviews/testing/treatment (PMID: 32010878; PMID: 29653941; PMID: 32558690; PMID: 28691284; PMID: 36758570; PMID: 37771793); diverticular/SUDD microbiome and fecal-bile-acid signals (PMID: 15884120; PMID: 27622371; PMID: 39514266; PMID: 40703297); treatment/relapse/MMC context (PMID: 21083027; PMID: 22340737; PMID: 31515325; PMID: 1687562; PMID: 10603298; PMID: 27507954); diet-soda/NCS context: carbonated-beverage GI review (PMID: 19502016), IBS diet association with carbonated drinks (PMID: 22676475), non-caloric sweetener GI-disease review (PMID: 31564473), NCS-free/contained diet RCT for functional GI symptoms (PMID: 35268070), aspartame microbiome RCT (PMID: 33171964), and NNS microbiome review (PMID: 37111090).
- Unresolved gaps: no confirmed Phnom Penh hydrogen/methane or BAD-test provider; medication availability is uncertain; the current meal-spacing/no-alcohol/stool-log experiment may make formal testing unnecessary if symptoms improve clearly or if watery urgency is absent.

```


---

## Original: topics/abdominal-spot-pain-map.md

```markdown
---
topic: Abdominal Spot-Pain Map
tags: [diverticular-disease, bloating, abdominal-pain, SUDD, IBS, SIBO, decision-router, diet-soda]
priority: urgent
last_updated: 2026-05-05
confidence: medium-high
abstract: >-
  Brief, low-grade, migrating spot pains with prominent post-meal bloating fit the symptom/motility
  branch better than diverticular hemorrhage or acute diverticulitis. The useful split is: fleeting
  migrating pains track gas/visceral-sensitivity/SIBO-SUDD-IBS overlap; persistent focal pain with
  fever, guarding, rising CRP/WBC, or deterioration triggers clinician/imaging logic; stool blood
  and iron drift stay on the separate bleeding branch.
related_topics:
  - bloating-vs-bleeding-risk
  - sibo-mmc
  - diverticular-disease
  - occult-stool-blood-workup
  - thirty-day-experiment
open_questions:
  - Do the logged spot pains fade during the alcohol/smoking/coffee-removal experiment, or persist despite cleaner exposures?
  - Does pain cluster with physical distension, stool/gas relief, meal stacking, walking, coffee, Coke Zero/diet soda, carbonation, or specific fermentable loads?
  - Do post-experiment calprotectin/CRP/CBC and stool-blood results keep this in the symptom branch or force structural escalation?
---

# Abdominal Spot-Pain Map

## Summary

The logged pattern so far is **brief, low-grade, migrating spot pain** superimposed on stronger bloating/distension. That is more compatible with a symptom/motility/visceral-sensitivity branch than with diverticular rebleeding or acute diverticulitis.

The important boundary rules:

1. **Pain does not explain stool blood.** FOB/stool RBC, ferritin/TSAT/Hb, and visible blood stay in the bleeding branch.
2. **Seconds-to-minutes migrating pains are usually lower-risk than persistent focal pain.** The red-flag version is same-location pain that persists/worsens, especially with fever, guarding, vomiting, systemic illness, or inflammatory-marker rise.
3. **Normal fecal calprotectin lowers the probability of active inflammatory colitis/diverticulitis**, but does not rule out SUDD/IBS-like pain, gas trapping, SIBO/MMC physiology, or intermittent bleeding.

## Current signal

From the active Tracker window, the spot-pain phenotype is mainly:

- location changes: lower left, lower right, center/lower abdomen, left of belly button, far right, occasional upper-left/chest-tightness note
- intensity usually **2-3/10**, with one baseline 1/10 at experiment start
- duration often **seconds to 1-2 minutes**, sudden on/off
- occurs with bloating scores around **5-7/10**
- no documented fever, persistent same-site pain, guarding, visible blood, or hemodynamic bleed symptoms in these spot-pain observations

That does **not** close the GI-source question because April stool blood was positive. It only says the current pains should not be treated as a reliable bleeding alarm.

## Decision map

| Pattern | More likely branch | Non-invasive discriminators | Action |
|---|---|---|---|
| Seconds-to-minutes pain, changes side/site, low intensity, appears/disappears suddenly | Gas movement, visceral hypersensitivity, abdominal-wall/position effect, functional bowel overlap | Location/duration log, relation to gas/toilet/posture/walking, abdomen-circumference delta | Track; avoid panic escalation unless pattern changes |
| Post-meal pressure/distension, circumference rises, worse after meal stacking/coffee/alcohol/diet soda/carbonation/fermentable load | Fermentation/load, carbonation distension, SIBO/MMC, IBS/SUDD overlap | Meal timing, 4-5h water-only gaps, circumference at baseline/peak, stool photos, coffee-free week and diet-soda-avoidance response | Continue experiment; avoid suspected triggers during the clean month; consider short low-fermentable trial only after the main month if still disruptive |
| Recurrent same-area lower-left pain lasting hours to >=24h, bowel-habit change, but no fever/systemic illness | SUDD or post-diverticular visceral hypersensitivity | Calprotectin, CRP/CBC trend, symptom score, stool pattern, response to fiber/meal pattern | GI discussion if persistent; symptom treatment, not bleed logic |
| Persistent focal pain that worsens, fever, vomiting, guarding, WBC/CRP jump, CRP >50 mg/L or marked systemic illness | Acute diverticulitis or complication | Temperature, pulse, CBC/diff, CRP, clinician exam; CT if clinically suspected | Do not manage as diet anxiety; clinician/urgent pathway |
| Visible blood, melena, dizziness/faintness, tachycardia, Hb/ferritin/TSAT drift, repeat FOB/RBC positive | Bleeding branch | CBC, ferritin/iron/TIBC/TSAT, FOB + stool direct exam, colonoscopy-quality check | Use occult-stool-blood algorithm |
| Upper abdominal/chest symptoms with sweating, dizziness, shortness of breath, left arm/hand symptoms | Cardiac/vascular rule-out branch in this Lp(a) profile | ECG, high-sensitivity troponin, vitals, clinician exam | Route to Recurrence Action Plan / possible ACS rule-out |

Cardiac-type upper-abdominal/chest recurrences are owned by [Recurrence Action Plan](#sec-recurrence-action); stool-blood/iron escalation is owned by [Occult Stool Blood Workup](#sec-occult-stool-blood).

“Urgent” here means high-priority KB tracking, not emergency care unless the red flags listed in [Whole-Profile Seriousness Triage](#sec-whole-profile-triage) appear.

## What to log now

Use the Tracker as a discriminator, not a worry journal. For pains that are stronger/new/persistent/unusual, log:

- exact location: left/right/center, above/below belly button, one-finger point if possible
- duration: seconds, minutes, hours, or continuous
- intensity: 0-10
- relation to meal timing, walking/exercise, toilet/gas, posture, coffee/tea, Coke Zero/diet soda/carbonation, alcohol/smoking slip, and large/stacked meals
- abdomen maximum-width circumference if bloating is present
- stool pattern/photo and any visible red/black area
- temperature or illness symptoms if the pain is persistent

Weak fleeting pains can remain sporadic logs. The actionable signal is clustering: same place, longer duration, rising intensity, systemic symptoms, or correlation with a modifiable trigger.

## Low-bleeding-risk symptom trials

Do these before medications unless red flags force clinician review:

1. **Finish the 30-day clean window** with no alcohol/smoking and the current coffee-free sub-trial. Avoid Coke Zero/diet colas while the symptom flare is being interpreted. This is the cleanest cause-removal test.
2. **Meal spacing / no grazing:** aim for 4-5 hour water-only gaps when practical. Improvement supports the MMC/fermentation branch but does not prove SIBO.
3. **Reduce meal stacking and large boluses:** split oversized meals; avoid adding dessert/juice/coffee directly on top of a main meal during the signal-finding period.
4. **Fiber tuning, not fiber fear:** keep the long-term plant/fiber direction, but titrate insoluble/very fermentable loads. If adding psyllium, start low and increase slowly because too much too fast can worsen gas.
5. **Short low-fermentable trial only if needed:** if bloating/spot pains remain disruptive after the clean month, try a time-limited 2-4 week low-FODMAP-style reduction with reintroduction, not a permanent restriction.
6. **Probiotics/CBM588-style branch:** reasonable as a symptom experiment if tolerated; evidence is low-certainty and it is not a bleed-prevention tool.
7. **Avoid NSAIDs.** Use non-NSAID pain approaches unless a clinician deliberately accepts bleeding risk.
8. **Rifaximin, prokinetics, mesalazine, or antibiotics:** clinician-led only. They are not self-treatment for brief migrating 2-3/10 pains.

## Evidence / context

- SUDD definitions remain unsettled, but abdominal pain is central; bloating and bowel-habit changes are common but not specific to SUDD (PMID: 39093005).
- Practical SUDD descriptions emphasize persistent/local abdominal pain with bowel-movement change and no systemic inflammation; healthy lifestyle and fiber are baseline, while rifaximin/mesalazine/probiotics remain symptom-management discussions rather than automatic steps (PMID: 37013200).
- Prolonged moderate-to-severe left-lower-quadrant pain plus higher fecal calprotectin is more SUDD-like than IBS-like symptoms in diverticulosis; Dag's normalized calprotectin and fleeting migrating pains point away from that classic SUDD pattern right now (PMID: 24583746; PMID: 18941760).
- Symptomatic diverticular disease can involve visceral hypersensitivity and low-grade neuro-immune changes, which fits pain that feels sharp and localized without proving active inflammation (PMID: 22276853).
- Diverticulosis and IBS-like symptoms frequently coexist; a 5,451-patient colonoscopy cohort found many symptomatic diverticulosis patients had IBS-like or unclassified pain rather than true SUDD (PMID: 33867449; PMID: 30407258).
- AGA diverticulitis guidance: clinical suspicion alone diagnoses diverticulitis correctly only about 40-65% of the time; CT is considered when diagnosis is uncertain, presentation is severe, symptoms fail to improve, or complications are suspected. High-risk features include vomiting, CRP >140 mg/L, WBC >15 x 10^9/L, or symptoms lasting >5 days before presentation (PMID: 33279517).
- IBS guidance supports a limited low-FODMAP trial for global symptoms and celiac/calprotectin testing in selected diarrhea-predominant cases; this supports a structured diet trial only after the current experiment, not endless restriction (PMID: 33315591).
- Probiotic evidence in diverticular disease is suggestive but low-to-very-low certainty; pain may improve more clearly than bloating, and formulas/durations vary (PMID: 41517338; PMID: 27622371).

## Integration note

Research outcome: **INTEGRATE.** This adds a dedicated symptom/pain router because the active queue item changes daily interpretation: brief migrating pains should be logged and patterned, not treated as occult-bleeding proof; persistent focal/systemic pain should trigger clinician/imaging logic; stool blood and iron drift stay separate.

```


---

## Original: topics/probiotics.md

```markdown
---
topic: Probiotics
tags: [supplements, microbiome, gastrointestinal]
priority: important
last_updated: 2026-05-04
confidence: medium
abstract: >-
  Probiotics remain symptom-management tools for SUDD/IBS-like overlap, not bleeding prevention
  or a general anti-inflammatory treatment. Use one base product only if logs show benefit;
  S. boulardii and CBM588 are optional targeted trials rather than permanent stack requirements.
related_topics: [clostridium-butyricum.md, diverticular-disease.md, eczema-diverticular-connection.md, recommended-supplement-adjustments.md]
open_questions:
  - Does stopping daily S. boulardii worsen logged symptoms enough to keep it?
---

# Probiotics

## Bottom line

For diverticular disease / SUDD, probiotics are reasonable symptom-management tools, but the evidence is still low-certainty. The strongest support is abdominal-pain relief; bloating benefit is not reliable, and probiotics do not explain or prevent stool blood. Adult atopic-dermatitis meta-analyses suggest modest strain-specific benefit, but this is still a logged symptom/skin trial, not a reason for indefinite probiotic stacking or commercial microbiome-test shopping.

## Evidence for diverticular disease

- PMID: 41517338 — 2025 systematic review/meta-analysis found abdominal-pain improvement, low/very-low certainty overall, and no clear bloating benefit.
- PMID: 41443984 — Fiesole Consensus says selected probiotics may help SUDD symptoms; it does not make them mandatory.
- Multi-strain formulations have broader support than single-strain products, but commercial species lists are not the same as trial-validated strains.

## Evidence for adult eczema / atopic dermatitis

- PMID: 40740395 and PMID: 37706436 — adult AD meta-analyses suggest modest SCORAD/severity improvement, with strain-specific signals and inconsistent cytokine/quality-of-life translation.
- Practical implication: a probiotic can earn a place if skin and gut logs improve, but eczema improvement is not proof of lower diverticular bleeding risk or lower cardiovascular risk.

## Current regimen logic

- TruNature 12-strain product: reasonable base if logs show symptom benefit; otherwise optional.
- S. boulardii: mainly diarrhea-oriented evidence; safe enough in a non-immunocompromised outpatient, but fungemia is a real rare-risk signal in ICU/central-line/immunocompromised settings. Cycling is not evidence-required.
- Do not run multiple probiotics indefinitely just because each has a plausible mechanism.

## CBM588 add-on

CBM588 now has one directly relevant indexed SUDD study:
- PMID: 41108431
- adequate symptom relief 77.4% vs 44.0% for cyclic rifaximin
- no significant difference in symptomatic flares

Interpretation:
- promising adjunct
- interesting because it adds butyrate production and spore resilience
- not proven best-in-class
- not a reason to replace the current broad multi-strain base

Practical position in this KB: keep one base probiotic only if useful; consider CBM588 as a separate targeted trial if sourced; do not frame any probiotic as bleeding prevention.

## References

- PMID: 41517338 — systematic review/meta-analysis of probiotics in diverticular disease
- PMID: 41443984 — Fiesole Consensus diverticular-disease guideline
- PMID: 41108431 — CBM588 vs cyclic rifaximin in SUDD
- PMID: 22423260 — S. boulardii efficacy/safety review
- PMID: 36806741 — Saccharomyces fungemia systematic review
- PMID: 40740395 — adult atopic-dermatitis probiotic systematic review/meta-analysis
- PMID: 37706436 — adult atopic-dermatitis probiotic systematic review/meta-analysis
- PMID: 39647502 — international consensus on microbiome testing in clinical practice

```


---

## Original: topics/clostridium-butyricum.md

```markdown
---
topic: Clostridium butyricum CBM588 (Miyairi Strain)
tags: [probiotics, diverticular-disease, SUDD, butyrate, bloating]
priority: important
last_updated: 2026-05-04
confidence: medium
abstract: >-
  CBM588/Miyarisan is a plausible targeted add-on for SUDD-type symptoms and barrier/butyrate
  biology. Evidence is promising but still thin; treat it as a controlled symptom trial
  candidate, not a proven replacement for the current probiotic base or a bleeding-risk
  intervention.
open_questions:
  - How much benefit does exact-strain CBM588 add on top of one base probiotic?
  - Which Phnom Penh Japanese-import pharmacy can confirm same-week Miyarisan/CBM588 stock?
---

# Clostridium butyricum CBM588 (Miyairi Strain)

## Bottom line

CBM588/Miyarisan is a plausible targeted probiotic trial for SUDD-type abdominal symptoms, mainly because it is a spore-forming butyrate producer and now has one directly relevant 12-month SUDD study. It is not proven bleeding prevention, not a replacement for a useful base probiotic, and not worth chasing unless the exact Miyairi/CBM588 strain can be sourced.

## Evidence quality

| Evidence | What it supports | Main limitation |
|---|---|---|
| PMID: 41108431 | Daily CBM588 had better adequate symptom relief than cyclic rifaximin over 12 months: 77.4% vs 44.0% | Retrospective, small, 56 completers; no flare advantage |
| PMID: 41517338 | Probiotics may improve abdominal pain in diverticular disease | Low/very-low certainty; bloating benefit did not clearly reach significance |
| PMID: 41443984 | Selected probiotics may help SUDD symptoms | Guideline-level permission, not a CBM588 mandate |

Interpretation: "promising adjunct worth a controlled symptom trial" is fair; "best probiotic" or "flare/bleed prevention" is too strong.

## Practical use

- Try only as a separate, logged symptom trial if the current base regimen is not enough.
- Do not stack CBM588 + multi-strain + daily S. boulardii indefinitely without log-visible benefit.
- Treat dosing as pragmatic, not optimized by evidence; start low and stop if bloating/stool pattern worsens.
- Live-probiotic cautions still apply in severe immunocompromise, central-line/ICU settings, or serious acute illness.

## Phnom Penh / Cambodia sourcing status

- Miyarisan's overseas page names Thailand/Singapore/Vietnam work but not Cambodia as a confirmed export market: https://www.miyarisan.com/en/overseas/
- Royal Phnom Penh Hospital can be asked as an institutional GI/pharmacy sourcing route: https://royalphnompenhhospital.com/network-hospital/
- Public Phnom Penh leads remain lead-only, not stock confirmation: Sun Pharmacy JP Telegram https://t.me/sun_pharmacy_jp and Facebook https://www.facebook.com/SUNPharmacyJP/

Buying rule: ask for "Miyarisan / Miyairi 588 / Clostridium butyricum CBM588," product photo, ingredient/strain label, and expiry date. Generic *Clostridium butyricum* is not automatically the studied CBM588/Miyairi strain.

## References / verification

- PMID: 41108431 — CBM588 vs cyclic rifaximin in SUDD.
- PMID: 41517338, PMID: 41443984 — broader probiotic/diverticular-disease evidence.
- Local-access verification retained from 2026-04-27; exact Phnom Penh stock remains unconfirmed.

```